Cyclerion Therapeutics, Inc. (CYCN)
| Market Cap | 15.48M +118.2% |
| Revenue (ttm) | 1.90M -12.6% |
| Net Income | -6.71M |
| EPS | -12.12 |
| Shares Out | 658.19K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 62,485 |
| Open | 26.04 |
| Previous Close | 29.75 |
| Day's Range | 19.74 - 26.88 |
| 52-Week Range | 3.42 - 59.36 |
| Beta | 1.75 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About CYCN
Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufa... [Read more]
Financial Performance
In 2025, Cyclerion Therapeutics's revenue was $2.07 million, an increase of 3.70% compared to the previous year's $2.00 million. Losses were -$3.53 million, 15.4% more than in 2024.
Financial StatementsNews
Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 Million
Advancing lead program KRSA-028 toward the clinic, with Phase 1 healthy volunteer data expected mid-2027 and interim proof-of-concept data in Alzheimer's patients anticipated by year-end 2027 or first...
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
WALTHAM, Mass.--(BUSINESS WIRE)---- $CYCN--Cyclerion Therapeutics, Inc. (“Cyclerion”) (Nasdaq: CYCN) and Korsana Biosciences, Inc. (“Korsana”), a privately-held biotechnology company discovering and d...
Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board
–Received Positive Pre-Investigational New Drug (“IND”) Written Feedback from the U.S. Food and Drug Administration (“FDA”)– –Clinical Advisory Board (“CAB”) Includes Key Leaders across Neuropsychiatr...
Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression
– Cyclerion Strengthens Development of Closed-Loop Anesthetic Platform through Strategic Collaboration Agreement with Medsteer – – Comprehensive Business Update and Path to Initiating Phase 2 Proof-of...
Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company
Cyclerion has entered into a licensing agreement with MIT, securing the intellectual property that will serve as the cornerstone of its strategic relaunch.
Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth
CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Company's next stage of growth.
Regina Graul, Ph.D., Promoted to Chief Executive Officer
CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced that Regina Graul, Ph.D.
Cyclerion Appoints Regina Graul, Ph.D., as President
– Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep expertise in company strategy –
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator
- Dina Katabi, Ph.D.: World leader in healthcare AI applications at MIT; inventor of groundbreaking wireless devices for passive assessment of symptoms, behavior, and treatment responses in neurologic...
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets
– Asset Purchase Agreement Closed; Cyclerion Received Equity Ownership in Tisento and Upfront Cash Payment –
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement
CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (“Cyclerion” or the “Company”) (Nasdaq: CYCN) today announced that it has received a formal notice from The Nasdaq Stoc...
Cyclerion Announces Reverse Stock Split
CAMBRIDGE, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (the “Company”, “Cyclerion Therapeutics”, “Cyclerion”) (Nasdaq: CYCN) announced today that it will effect a reverse stoc...
Cyclerion Announces Definitive Agreement for Zagociguat and CY3018
Certain Cyclerion shareholders and new investors have agreed to invest $81M to launch a new company targeting diseases of mitochondrial dysfunction
Cyclerion Announces Corporate Updates and Q1 2023 Financial Results
Definitive agreement reached with new company (“NewCo”) established by certain Cyclerion shareholders and new investors
Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement
CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that the Board of Directors of the Company, acting solely by all of its independent and...
Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases
CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments for serious diseases, to...
Cyclerion Reports Corporate Update and Full Year 2022 Financial Results
CAMBRIDGE, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced corporate updates including advances in its zagociguat (formerly CY6463) mitochondrial ...
Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that the Board of Directors of the Company acting solely by all of its independent and d...
Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy
Recent positive MELAS clinical study data drive urgency to deliver potential first-ever therapy for patients with rare, genetic mitochondrial diseases
Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results
Positive topline results for CY6463 announced in two clinical studies in patients with Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Cognitive Impairment Associ...
Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)
Study data demonstrate positive effects of CY6463 on cognition and inflammation after two weeks of dosing in patients with stable schizophrenia on standard of care
Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics' Board of Directors
Renowned neuroscience leader to further long-term clinical research strategy and external collaborations Renowned neuroscience leader to further long-term clinical research strategy and external colla...
Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation
Data for CY6463, a first-in-class, CNS-penetrant, sGC stimulator, demonstrate safety and positive effects across biomarkers of disease in MELAS patients
Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation
Company to discuss positive topline and additional clinical data for CY6463 in MELAS patients
Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease
CY6463 alleviated mitochondrial dysfunction and reduced inflammation in preclinical models of mitochondrial complex 1 deficiency